Jasper Therapeutics, Inc. (JSPR) Stock

Jasper Therapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of therapeutic solutions for hematopoietic stem cell transplantation and gene therapies. The company is dedicated to advancing conditioning agents and stem cell engineering technologies aimed at broadening the application of stem cell transplantation and ex vivo gene therapy.

At the forefront of Jasper Therapeutics' portfolio is JSP191, its lead product candidate undergoing clinical trials. JSP191 functions as a conditioning antibody designed to deplete hematopoietic stem cells from the bone marrow of patients prior to allogeneic stem cell therapy or stem cell gene therapy. This approach enhances the effectiveness and safety of these procedures. Additionally, Jasper Therapeutics is actively pursuing the development of engineered hematopoietic stem cell products to address critical challenges associated with both allogeneic and autologous gene-edited stem cell grafts.

Headquartered in Redwood City, California, Jasper Therapeutics leverages cutting-edge research and development to pioneer advancements in the field of hematopoietic stem cell transplantation and gene therapy. The company's innovative approach holds promise for transforming treatment options and improving outcomes for patients facing hematologic disorders and other conditions requiring stem cell-based therapies.